US EditionKimberly-Clark buying Tylenol maker Kenvue in $48.7 billion deal
The $48.7 billion deal combines top consumer health brands to create a company with approximately $32 billion in annual revenue, pending shareholder approval.
- In a Monday statement, Kimberly‑Clark Corp. said it will acquire Kenvue Inc., which makes Tylenol, in a $48.7 billion deal.
- After a months‑long strategic review that began in July, Kenvue Inc. was spun out of Johnson & Johnson in 2023 and faced leadership changes and mounting litigation risks, the Kenvue board said.
- The transaction is structured as cash plus stock, with Kenvue shareholders receiving $3.50 per share plus 0.14625 Kimberly‑Clark shares, implying $21.01 per share and a $40.32 billion equity value, while Kimberly‑Clark shareholders will own about 54% of the combined company.
- Kimberly‑Clark shares plunged 16% after the announcement, while Michael Hsu, Kimberly‑Clark chairman and chief executive officer, will lead the combined company; the deal is expected to close in the second half of next year.
- The deal also surfaced amid political scrutiny after President Donald Trump linked Tylenol to autism, which Kenvue disputed; the combined company will have roughly $32 billion in annual revenues.
277 Articles
277 Articles
Kimberly-Clark Takeover Offers $48 Billion of Pain Relief to Tylenol-Maker Kenvue
At least Kimberly-Clark will have unlimited access to free Tylenol. The toiletries giant announced an agreement Monday to acquire Kenvue for $48.7 billion in stock and cash. It’s a big bet on the Tylenol-maker, whose shares had plummeted some 30% in the days since a bombshell White House allegation in September linking use of the popular pain reliever by pregnant women to autism. Do You Need a Band-Aid? On its surface, the deal makes plenty of s…
These 2 Dividend Kings Are Combining in a $48.7 Billion Megadeal. Is It A Win-Win for Dividend Investors?
Key PointsKimberly-Clark is merging with Kenvue. The deal brings together two companies with long histories of growing their dividends. The transaction creates a larger-scale company that will save money, but it comes with risks. 10 stocks we like better than Kenvue › Kimberly-Clark (NASDAQ: KMB) has agreed to acquire Kenvue (NYSE: KVUE) in a cash-and-stock deal, valuing Kenvue at $48.7 billion. The merger will create a $32 billion global leader…
The announcement comes weeks after President Trump made claims that linked Tylenol to autism in unborn babies of pregnant women, which brought down Kenvue’s actions. The company has rejected the Trump administration’s accusations.
Coverage Details
Bias Distribution
- 61% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
